Double maintains 1 strategies that include CATX - Perspective Therapeutics, Inc.
Yahoo
SEATTLE (AP) — Perspective Therapeutics, Inc. CATX) on Monday reported a loss of $18.2 million in its first quarter. On a per-share basis, the Seattle-based company said it had a loss of 25 cents.
Yahoo
First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroend
Yahoo
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. Bank of America Global Healthcare ConferenceDate: Tuesday, May 13, 2025Format: Fireside ChatTime:
Yahoo
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein
Yahoo
SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company’s [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO pla
Yahoo
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DV | 0.01% | $2.34B | -23.73% | 0.00% |
FSP | 0.03% | $184.35M | -6.81% | 2.31% |
CHD | -0.07% | $23.29B | -11.36% | 1.23% |
SRDX | -0.10% | $400.81M | -17.75% | 0.00% |
AGL | -0.11% | $1.06B | -54.30% | 0.00% |
RDDT | 0.13% | $20.96B | +101.47% | 0.00% |
KO | -0.21% | $308.23B | +13.09% | 2.75% |
BJ | 0.21% | $14.71B | +39.60% | 0.00% |
NWN | 0.24% | $1.64B | +5.82% | 4.81% |
VHC | -0.29% | $34.69M | +74.89% | 0.00% |
FLYW | 0.33% | $1.38B | -32.48% | 0.00% |
HEES | -0.33% | $3.52B | +99.54% | 1.15% |
AOSL | -0.33% | $698.17M | -13.91% | 0.00% |
MCY | 0.34% | $3.43B | +6.94% | 2.05% |
YORW | -0.44% | $469.88M | -15.42% | 2.64% |
AEP | -0.49% | $54.28B | +9.80% | 3.61% |
LNT | 0.53% | $15.85B | +18.74% | 3.19% |
CNC | -0.53% | $29.89B | -22.14% | 0.00% |
ATO | 0.54% | $24.77B | +31.55% | 2.15% |
KR | 0.57% | $44.68B | +24.17% | 1.89% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KURA | 54.82% | $515.12M | -74.11% | 0.00% |
EYPT | 39.76% | $393.60M | -54.31% | 0.00% |
YMAB | 38.87% | $174.80M | -67.43% | 0.00% |
DNTH | 38.67% | $603.00M | -28.57% | 0.00% |
VTYX | 38.35% | $86.11M | -75.70% | 0.00% |
ROIV | 37.63% | $7.68B | -5.70% | 0.00% |
IMNM | 37.44% | $696.10M | -44.44% | 0.00% |
RXRX | 36.20% | $1.73B | -55.31% | 0.00% |
BEAM | 35.94% | $1.73B | -27.49% | 0.00% |
RCKT | 35.76% | $724.54M | -71.26% | 0.00% |
IONS | 35.76% | $5.25B | -12.31% | 0.00% |
ARWR | 35.49% | $2.12B | -38.64% | 0.00% |
SYRE | 35.46% | $877.54M | -61.53% | 0.00% |
OCUL | 34.79% | $1.14B | +14.35% | 0.00% |
ATXS | 34.01% | $225.17M | -57.69% | 0.00% |
SPRY | 33.87% | $1.20B | +34.01% | 0.00% |
COGT | 33.78% | $543.09M | -36.14% | 0.00% |
IR | 33.68% | $33.49B | -9.19% | 0.12% |
SHC | 33.26% | $3.62B | +11.66% | 0.00% |
CPA | 32.72% | $4.21B | -6.57% | 6.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
YEAR | 0.03% | $1.40B | 0.25% |
SHY | -0.03% | $24.03B | 0.15% |
USFR | -0.14% | $18.91B | 0.15% |
BIL | 0.15% | $45.95B | 0.1356% |
VMBS | 0.15% | $14.29B | 0.03% |
IBTF | 0.19% | $2.12B | 0.07% |
CGCB | 0.27% | $2.19B | 0.27% |
SHYM | -0.27% | $322.93M | 0.35% |
FTSM | 0.29% | $6.54B | 0.45% |
OUNZ | -0.31% | $1.64B | 0.25% |
AAAU | -0.38% | $1.47B | 0.18% |
TBIL | -0.40% | $5.76B | 0.15% |
BNDX | 0.40% | $64.67B | 0.07% |
SGOL | -0.46% | $5.06B | 0.17% |
CMBS | 0.48% | $427.55M | 0.25% |
IAU | -0.50% | $45.68B | 0.25% |
GLDM | -0.52% | $14.42B | 0.1% |
OWNS | 0.56% | $134.57M | 0.3% |
GLD | -0.57% | $96.70B | 0.4% |
BAR | -0.66% | $1.10B | 0.1749% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -29.30% | $109.64M | 0.85% |
TAIL | -28.01% | $140.49M | 0.59% |
BTAL | -25.67% | $361.41M | 1.43% |
TPMN | -11.47% | $31.54M | 0.65% |
IVOL | -10.37% | $353.94M | 1.02% |
TFLO | -9.78% | $7.06B | 0.15% |
CTA | -9.50% | $1.05B | 0.76% |
WTMF | -8.84% | $156.80M | 0.65% |
UNG | -8.56% | $371.83M | 1.06% |
FXY | -7.99% | $838.61M | 0.4% |
ULST | -7.47% | $637.77M | 0.2% |
FTSD | -7.46% | $212.46M | 0.25% |
SCHO | -6.62% | $10.87B | 0.03% |
STPZ | -6.56% | $446.46M | 0.2% |
XBIL | -6.39% | $782.40M | 0.15% |
TBLL | -6.19% | $2.46B | 0.08% |
CARY | -5.92% | $347.36M | 0.8% |
SPTS | -5.81% | $5.76B | 0.03% |
XONE | -5.69% | $603.24M | 0.03% |
UTWO | -5.41% | $387.71M | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SNOW | -16.82% | $61.05B | +10.86% | 0.00% |
CBOE | -9.96% | $22.95B | +20.67% | 1.12% |
CRNC | -8.57% | $402.30M | +90.18% | 0.00% |
PULM | -8.51% | $23.82M | +239.64% | 0.00% |
CCRN | -6.84% | $457.33M | -5.30% | 0.00% |
BNED | -5.92% | $371.19M | -38.80% | 0.00% |
SAVA | -5.40% | $99.03M | -90.49% | 0.00% |
IBEX | -4.84% | $378.57M | +86.74% | 0.00% |
EXC | -4.76% | $43.84B | +12.45% | 3.59% |
PARAA | -4.69% | $15.22B | +3.06% | 0.88% |
SEG | -4.61% | $239.93M | -26.61% | 0.00% |
FMTO | -4.56% | $45.74M | -99.96% | 0.00% |
EW | -4.48% | $45.10B | -14.68% | 0.00% |
CHCT | -4.31% | $464.74M | -31.81% | 11.34% |
AQB | -4.10% | $2.96M | -61.58% | 0.00% |
AMT | -3.39% | $99.10B | +8.59% | 3.09% |
OMER | -3.19% | $230.31M | +19.34% | 0.00% |
VSA | -3.05% | $7.04M | -49.24% | 0.00% |
AWK | -2.59% | $27.37B | +4.54% | 2.22% |
UTI | -2.59% | $1.84B | +121.04% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 43.33% | $4.85B | 0.35% |
GNOM | 41.67% | $40.65M | 0.5% |
ARKG | 40.84% | $944.78M | 0.75% |
IBB | 38.90% | $5.22B | 0.45% |
FBT | 35.87% | $994.71M | 0.56% |
ROBO | 35.63% | $983.03M | 0.95% |
PBE | 35.01% | $214.12M | 0.58% |
KJUL | 35.01% | $113.35M | 0.79% |
IWC | 34.91% | $766.88M | 0.6% |
AOA | 34.45% | $2.30B | 0.15% |
SPGM | 34.28% | $1.04B | 0.09% |
IOO | 34.19% | $6.24B | 0.4% |
ROBT | 34.14% | $462.06M | 0.65% |
VT | 34.11% | $45.29B | 0.06% |
ERTH | 34.09% | $150.05M | 0.67% |
ACWI | 34.04% | $21.24B | 0.32% |
BBLU | 33.94% | $255.89M | 0.15% |
GRID | 33.87% | $2.22B | 0.56% |
CGBL | 33.85% | $2.14B | 0.33% |
IWO | 33.84% | $11.36B | 0.24% |
Current Value
$2.411 Year Return
Current Value
$2.411 Year Return